Healthcare / BiotechnologyTaiwan
$16.40
-0.20 (-1.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $69.9M · quality 70.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.4B
P/E
24.8x
↑EV/EBITDA
10.5x
↓ROE
4.3%
↑Gross Margin
62.7%
↑Debt/Equity
0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.9%
FCF CAGR
+1.9%
FCF margin
17.4%
FCF / Net income
1.22x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $401.2M · net income $57.2M · FCF $69.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $401.2M | $401.2M | $385.4M | $318.0M | $368.5M |
| Net Income | $57.2M | $57.2M | $57.3M | $33.0M | $57.0M |
| EBITDA | $134.6M | $134.6M | $140.0M | $93.9M | $117.4M |
| EPS | — | — | 0.66 | 0.38 | 0.66 |
| Gross Margin | 62.7% | 62.7% | 61.8% | 66.4% | 69.7% |
| Operating Margin | 14.6% | 14.6% | 10.4% | 2.4% | 16.3% |
| Net Margin | 14.3% | 14.3% | 14.9% | 10.4% | 15.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.08 | 0.08 | 0.09 | 0.04 | 0.03 |
| Current Ratio | 4.28 | 4.28 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $69.9M | $69.9M | $79.7M | $-941000.00 | $66.0M |
| Returns | |||||
| ROE | 4.3% | 4.3% | 4.2% | 2.5% | 4.2% |
| Valuation | |||||
| P/E | 24.85 | 24.85 | 30.38 | 64.21 | 35.45 |
| EV/EBITDA | 10.53 | 10.53 | 12.48 | 22.52 | 16.42 |
| P/B | 1.06 | 1.06 | 1.29 | 1.60 | 1.50 |
| Growth & Yield | |||||
| Revenue Growth | 4.1% | 4.1% | 21.2% | -13.7% | — |
| EPS Growth | — | — | 73.7% | -42.4% | — |
| Dividend Yield | 4.9% | 4.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-13.7%
Start / end P/E
n/dx → n/dx
EPS bridge
0.66 → n/d
Residual
-18.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.